| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 4,473 | 5,230 | ||
| Subscription receivable | 0 | 0 | ||
| Prepaid expenses and other current assets | 428 | 717 | ||
| Total current assets | 4,901 | 5,947 | ||
| Other assets | 101 | 101 | ||
| Total assets | 5,002 | 6,048 | ||
| Accounts payable | 434 | 202 | ||
| Accrued expenses | 164 | 145 | ||
| Total current liabilities | 598 | 347 | ||
| Royalty purchase liability | 151,049 | 151,049 | ||
| Warrant liability | 0 | 0 | ||
| Total liabilities | 151,647 | 151,396 | ||
| Series b redeemable convertible preferred stock, 0.001 par value 10,000,000 shares authorized 119,318 shares issued and outstanding at september 30, 2025 and december 31, 2024-Series BRedeemable Convertible Preferred Stock | 2,577 | 2,597 | ||
| Common stock, 0.001 par value 200,000,000 shares authorized 75,462,390 shares issued and outstanding at september 30, 2025 and december 31, 2024 | 75 | 75 | ||
| Additional paid-in capital | 311,121 | 311,010 | ||
| Accumulated deficit | -460,418 | -459,030 | ||
| Total stockholders' deficit | -149,222 | -147,945 | ||
| Total liabilities, redeemable convertible preferred stock and stockholders' deficit | 5,002 | 6,048 | ||
Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc. (GRTX)